Loading...

Jonathan S Lopresti, MD

Title(s)Associate Professor of Clinical Medicine
SchoolKeck School of Medicine of USC
Phone+1 323 226 4632
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    Department of Medicine, USC1997Attending of the Year for Internal Medicine
    Keck School of Medicine of USC1998Professor of the Year for Fourth Year Students
    Keck School of Medicine of USC2015Faculty Teaching Award, Year II
    Keck School of Medicine of USC2015Faculty Teaching Award, Year IV

    Collapse Overview 
    Collapse Overview
    A native of Los Angeles, Dr. LoPresti received both his medical degree and his Ph.D. in physiology from the University of Southern California. He first joined the Trojan family in 1974 as a biology undergraduate and finished his residency at the LAC+USC Medical Center ten years later. Dr. LoPresti has contributed to over fifty presentations, recently lecturing on a case of an aggressive Papillary Thyroid Cancer arising in the third trimester of pregnancy. In addition, he has had leadership roles in the American Thyroid Association and has been published in numerous journals, abstracts and book chapters.

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Schmidt RL, LoPresti JS, McDermott MT, Zick SM, Straseski JA. Does Reverse Triiodothyronine Testing Have Clinical Utility? An Analysis of Practice Variation Based on Order Data from a National Reference Laboratory. Thyroid. 2018 Jul; 28(7):842-848. PMID: 29756541.
      View in: PubMed
    2. Spencer C, Petrovic I, Fatemi S, LoPresti J. Serum thyroglobulin (Tg) monitoring of patients with differentiated thyroid cancer using sensitive (second-generation) immunometric assays can be disrupted by false-negative and false-positive serum thyroglobulin autoantibody misclassifications. J Clin Endocrinol Metab. 2014 Dec; 99(12):4589-99. PMID: 25226290; PMCID: PMC4297889.
    3. Angell TE, Lechner MG, Nguyen CT, Salvato VL, Nicoloff JT, LoPresti JS. Clinical features and hospital outcomes in thyroid storm: a retrospective cohort study. J Clin Endocrinol Metab. 2015 Feb; 100(2):451-9. PMID: 25343237.
      View in: PubMed
    4. Angell TE, Lechner MG, Jang JK, LoPresti JS, Epstein AL. MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. Clin Cancer Res. 2014 Dec 01; 20(23):6034-44. PMID: 25294906; PMCID: PMC4252612.
    5. Spencer C, LoPresti J, Fatemi S. How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies. Curr Opin Endocrinol Diabetes Obes. 2014 Oct; 21(5):394-404. PMID: 25122493; PMCID: PMC4154792.
    6. Kaptein EM, LoPresti JS, Kaptein MJ. Is an isolated TSH elevation in chronic nonthyroidal illness "subclinical hypothyroidism"? J Clin Endocrinol Metab. 2014 Nov; 99(11):4015-26. PMID: 25166720.
      View in: PubMed
    7. Angell TE, Lechner MG, Jang JK, Correa AJ, LoPresti JS, Epstein AL. BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration. Thyroid. 2014 Sep; 24(9):1385-93. PMID: 24955518; PMCID: PMC4148060.
    8. Angell TE, Spencer CA, Rubino BD, Nicoloff JT, LoPresti JS. In search of an unstimulated thyroglobulin baseline value in low-risk papillary thyroid carcinoma patients not receiving radioactive iodine ablation. Thyroid. 2014 Jul; 24(7):1127-33. PMID: 24697314.
      View in: PubMed
    9. Spencer C, Fatemi S, Singer P, Nicoloff J, Lopresti J. Serum Basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer. Thyroid. 2010 Jun; 20(6):587-95. PMID: 20470203.
      View in: PubMed
    10. Spencer CA, Lopresti JS. Measuring thyroglobulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer. Nat Clin Pract Endocrinol Metab. 2008 Apr; 4(4):223-33. PMID: 18268520.
      View in: PubMed
    11. Fatemi S, LoPresti JS. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003 Sep; 88(9):4507-8; author reply 4508-10. PMID: 12970333.
      View in: PubMed